retatrutide triple agonist glp-1 gip glucagon receptor Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data retatrutide peptide | peptidesskin

We have never had a category of medication which has tempted 1.25 million people to say, actually, Im going to forgo the NHS, Im going to look after myself and self-medicate. He estimates that 80% of GLP-1 users are women and a fifth are men, even though the obesity split in the population is 50-50

31 If solid foods are difficult, nutrient-dense protein shakes or meal replacement shakes can be a temporary option

As one endocrinologist at KU Leuven told Medscape: I dont think we have seen enough data to be able to say this one is far more promising than the others

Across the three pivotal trials, peak mean body-weight reductions rank retatrutide 12 mg at 24.2% (48 weeks, Phase 2), tirzepatide 15 mg at 22.5% (72 weeks, Phase 3), and semaglutide 2.4 mg at 14.9% (68 weeks, Phase 3) [1][2][5]

Our Miami office is conveniently located right off of U.S

With clinically meaningful weight loss and cardiovascular outcomes in patients with type 2 diabetes, GLP-1RAs were further assessed in patients with overweight or obesity without type 2 diabetes in the 2021 STEP-1 trial and 2022 SURMOUNT-1 trial